[HTML][HTML] Consensus regarding diagnosis and management of atypical hemolytic uremic syndrome

H Lee, E Kang, HG Kang, YH Kim, JS Kim… - The Korean Journal …, 2020 - ncbi.nlm.nih.gov
Thrombotic microangiopathy (TMA) is defined by specific clinical characteristics, including
microangiopathic hemolytic anemia, thrombocytopenia, and pathologic evidence of …

The footprints of mitochondrial impairment and cellular energy crisis in the pathogenesis of xenobiotics-induced nephrotoxicity, serum electrolytes imbalance, and …

R Heidari - Toxicology, 2019 - Elsevier
Fanconi's Syndrome (FS) is a disorder characterized by impaired renal proximal tubule
function. FS is associated with a vast defect in the renal reabsorption of several chemicals …

The nephrotoxicity of drugs used in causal oncological therapies

J Hałka, S Spaleniak, G Kade, S Antosiewicz… - Current …, 2022 - mdpi.com
In recent years, a dynamic development of oncology has been observed, resulting from the
increasingly frequent occurrence of neoplasms and therefore, increasing population of …

Thrombotic microangiopathy associated with gemcitabine use: Presentation and outcome in a national French retrospective cohort

F Daviet, F Rouby, P Poullin… - British journal of …, 2019 - Wiley Online Library
Aims Gemcitabine has been associated with thrombotic microangiopathy (TMA). We
conducted a national retrospective study of gemcitabine‐associated TMA (G‐TMA). Methods …

Phase I dose-escalation study of milciclib in combination with gemcitabine in patients with refractory solid tumors

S Aspeslagh, K Shailubhai, R Bahleda… - Cancer Chemotherapy …, 2017 - Springer
Background This phase I trial evaluated the safety and tolerability of milciclib, an inhibitor of
multiple cyclin-dependent kinases and tropomycin receptor kinase A, in combination with …

[HTML][HTML] Antitumor activity of the novel HDAC inhibitor CUDC-101 combined with gemcitabine in pancreatic cancer

M Ji, Z Li, Z Lin, L Chen - American Journal of Cancer Research, 2018 - ncbi.nlm.nih.gov
Histone deacetylase (HDAC) is overexpressed in multiple cancers including pancreatic
cancer (PC). However, the effects of histone deacetylase inhibitor (HDACi) on apoptosis and …

Solute Carrier Nucleoside Transporters in Hematopoiesis and Hematological Drug Toxicities: A Perspective

SS Ali, R Raj, T Kaur, B Weadick, D Nayak, M No… - Cancers, 2022 - mdpi.com
Simple Summary Anticancer nucleoside analogs are promising treatments that often result
in damaging toxicities and therefore ineffective treatment. Mechanisms of this are not well …

Bevacizumab-induced atypical hemolytic uremic syndrome and treatment with eculizumab

A Vakiti, D Singh, R Pilla… - Journal of Oncology …, 2019 - journals.sagepub.com
Bevacizumab (Avastin) is a recombinant humanized monoclonal antibody used for the
management of various solid malignancies including colorectal, lung, brain, renal, and …

[HTML][HTML] Gemcitabine inhibits immune escape of pancreatic cancer by down regulating the soluble ULBP2 protein

X Lin, M Huang, F Xie, H Zhou, J Yang, Q Huang - Oncotarget, 2016 - ncbi.nlm.nih.gov
Due to early onset of local invasion and distant metastasis, pancreatic cancer is the most
lethal human malignant tumor, with a 5 year survival rate of less than 5%. As a effective …

Rapid improvement in gemcitabine-associated thrombotic microangiopathy after a single dose of eculizumab: case report and review of the literature

ST Burns, L Damon, N Akagi, Z Laszik… - Anticancer …, 2020 - ar.iiarjournals.org
We present here the case of a 39-year-old man with metastatic pancreatic carcinoma
receiving chemotherapy with the combination of gemcitabine and nab-paclitaxel as part of a …